Biogen Idec Inc, the maker of multiple sclerosis drugs Avonex, Tysabri and Tecfidera, boosted its 2013 forecast after Tecfidera sales topped analysts’ third-quarter estimates.

Revenue this year will grow by 23 percent to 25 percent, with adjusted earnings of $8.65 to $8.85 a share, the Weston, Massachusetts-based drugmaker said today in a statement. The company previously had projected revenue gaining 22 percent to 23 percent and adjusted earnings of $8.25 to $8.50 a share.